metricas

Acta Otorrinolaringológica Española

Sugerencias
Acta Otorrinolaringológica Española Análisis de la supervivencia de los pacientes con tumores malignos de cabeza y ...
Información de la revista
Vol. 76. Núm. 2.
Páginas 71-140 (Marzo - Abril 2025)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
975
Vol. 76. Núm. 2.
Páginas 71-140 (Marzo - Abril 2025)
Artículo original

Análisis de la supervivencia de los pacientes con tumores malignos de cabeza y cuello diagnosticados durante la pandemia de COVID-19

Survival of patients with malignant head and neck tumors diagnosed during the COVID-19 pandemic
Visitas
975
Xavier Leóna,b,c,
Autor para correspondencia
xleon@santpau.cat

Autor para correspondencia.
, Cristina Valeroa, Anna Holgadoa, Cristina Vázquez-Lópeza, Rosselin Vásqueza, Arnau Parelladaa, Miquel Quera,b, Albert Pujola
a Servicio de Otorrinolaringología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España
b Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, España
c UVIC, Universitat Central de Catalunya, Vic, Barcelona, España
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Resumen
Objetivo

La pandemia de COVID-19 alteró significativamente el acceso a la atención sanitaria a nivel mundial. Pocos estudios han evaluado si la pandemia afectó negativamente a los pacientes con tumores malignos de cabeza y cuello diagnosticados durante este periodo. Este estudio se propone determinar si existieron diferencias en los resultados oncológicos entre los pacientes diagnosticados durante la pandemia de COVID-19 y aquellos diagnosticados previamente.

Material y métodos

Se realizó un estudio retrospectivo en pacientes con tumores malignos de cabeza y cuello diagnosticados durante la pandemia y en los cinco años anteriores en un centro terciario.

Resultados

La cohorte analizada incluyó 872 pacientes diagnosticados entre marzo de 2015 y febrero de 2022. El menor número de diagnósticos ocurrió durante el trimestre que denominamos COVID-4 (marzo de 2020 a junio de 2020), coincidiendo con la fase más estricta del confinamiento. No hubo cambios significativos en las características de los pacientes ni en el tipo de tratamiento recibido debido a la pandemia. No se observaron diferencias significativas en la supervivencia específica a los 3años entre los pacientes diagnosticados y tratados durante el periodo COVID-12 (marzo de 2020 a febrero de 2021, 73,0% de supervivencia) y los tratados durante los cinco años anteriores (marzo de 2015 a febrero de 2020, 70,6% de supervivencia, p=0,377).

Conclusiones

La pandemia de COVID-19 condujo a una disminución en el número de diagnósticos de tumores malignos de cabeza y cuello durante la fase de confinamiento más estricto. Sin embargo, no se observaron diferencias significativas en los resultados oncológicos como consecuencia de la pandemia.

Palabras clave:
COVID-19
SARS-CoV-2
Tumor maligno de cabeza y cuello
Carcinoma de células escamosas de cabeza y cuello
Pandemia
Resultados oncológicos
Abstract
Objective

The COVID-19 pandemic significantly affected healthcare access worldwide. Few studies have analyzed whether the pandemic negatively impacted patients with head and neck malignant tumors diagnosed during this period. This study aims to determine if there were differences in oncological outcomes between patients diagnosed during the pandemic and those diagnosed previously.

Material and methods

A retrospective study was conducted on patients with malignant head and neck tumors diagnosed during the pandemic and the previous five years at a tertiary center.

Results

The study cohort included 872 patients diagnosed between March 2018 and February 2022. The quarter with the fewest diagnoses was the COVID-4 period (March-2020 to June-2020), coinciding with the strictest lockdown phases. There were no significant changes in patient characteristics or treatment types due to the pandemic. No significant differences in 3-year disease-specific survival were observed between patients diagnosed and treated during the COVID period (March-2020 to February-2021, disease-specific survival 73.0%) and those treated during the previous five years (March-2015 to February-2020, disease-specific survival 70.6%, P=.377).

Conclusions

The COVID-19 pandemic led to a decrease in the number of diagnoses of malignant head and neck tumors during the strictest lockdown phases in our country. However, no statistically significant differences in oncological outcomes were observed as a consequence of the pandemic.

Keywords:
COVID-19
SARS-CoV-2
Head and neck malignant tumor
Head and neck squamous cell carcinoma
Pandemic
Oncological results

Artículo

Opciones para acceder a los textos completos de la publicación Acta Otorrinolaringológica Española
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
M. Amador, X. Matias-Guiu, G. Sancho-Pardo, J. Contreras Martinez, J.C. de la Torre-Montero, A. Peñuelas Saiz, et al.
Impact of the COVID-19 pandemic on the care of cancer patients in Spain.
ESMO Open., 6 (2021), pp. 100157
[2]
J. Semprini, N.A. Pagedar, E.A. Boakye, N. Osazuwa-Peters.
Head and neck cancer incidence in the United States before and during the COVID-19 pandemic.
JAMA Otolaryngol Head Neck Surg., 150 (2024), pp. 193-200
[3]
M.C. Pinto Pereira, J.C. Hasse Fernandes, G.V. Oliveira Fernandes, F. Nor, T. Marques, P. Couto.
Impact of the COVID-19 pandemic period on patients with head and neck carcinoma: A systematic review.
Diseases., 11 (2023), pp. 61
[4]
X. León, C. Orús, M. Quer.
Diseño, mantenimiento y explotación de una base de datos oncológica para pacientes con tumores malignos de cabeza y cuello.
Acta Otorrinolaringol Esp., 53 (2002), pp. 185-190
[5]
R.C. Schoonbeek, D.V.C. de Jel, B.A.C. van Dijk, S.M. Willems, E. Bloemena, F.J.P. Hoebers, et al.
Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: A nationwide population-based analysis.
Radiother Oncol., 167 (2022), pp. 42-48
[6]
K.L. Kiong, E.M. Diaz, N.D. Gross, E.M. Diaz Jr., E.Y. Hanna.
The impact of COVID-19 on head and neck cancer diagnosis and disease extent.
Head Neck., 43 (2021), pp. 1890-1897
[7]
M.S. De Castro, B.M.S.M. Machado, M.C.F. Barbosa, L.F.F. Soares, F.F. Sperandio, M.L. de Carli, et al.
Impact of the COVID-19 pandemic on head and neck cancer patients: Systematic review and meta-analysis.
Quintessence Int., 54 (2023), pp. 320-327
[8]
P. Yao, V. Cooley, W. Kuhel, A. Tassler, V. Banuchi, S. Long, et al.
Times to diagnosis, staging, and treatment of head and neck cancer before and during COVID-19.
[9]
K. Metzger, J. Mrosek, S. Zittel, M. Pilz, T. Held, S. Adeberg, et al.
Treatment delay and tumor size in patients with oral cancer during the first year of the COVID-19 pandemic.
Head Neck., 43 (2021), pp. 3493-3497
[10]
F. Tevetoğlu, S. Kara, C. Aliyeva, R. Yildirim, H.M. Yener.
Delayed presentation of head and neck cancer patients during COVID-19 pandemic.
Eur Arch Otorhinolaryngol., 278 (2021), pp. 5081-5085
[11]
F. Jahanshahi, M. Asadi, A. Movahedi.
The stage of head and neck diagnosed malignancies in COVID-19 outbreak versus before outbreak: A retrospective study.
Cancer Rep (Hoboken)., 6 (2023), pp. e1801
[12]
R.N. Solis, M. Mehrzad, S. Faiq, R.P. Frusciante, H.K. Sekhon, M. Abouyared, et al.
The impact of COVID-19 on head and neck cancer treatment: Before and during the pandemic.
[13]
M. Gete, S.H. Huang, J. Ringash, J. Irish, J. Su, Y. Ballal, et al.
Causes and impact of delays during the COVID-19 pandemic on head and neck cancer diagnosis.
Head Neck., 46 (2024), pp. 2197-2205
[14]
T. Vanderhaegen, A. Pierache, G. Mortuaire, B. Rysman, R. Nicot, D. Chevalier, et al.
The first wave of COVID-19 did not cause longer wait times in head and neck cancer Experience of a French expert center.
Eur Ann Otorhinolaryngol Head Neck Dis., 139 (2022), pp. 261-267
[15]
S. Heckel, C. Bohr, J. Meier, J. Maurer, J. Kuenzel, K. Mueller, et al.
Head and neck oncology management in the time of COVID-19: Results of a head and neck cancer center.
J Cancer Res Clin Oncol., 149 (2023), pp. 12081-12087
[16]
K. Clements, A. Thapa, A. Cowell, D. Conway, C.M. Douglas, C. Paterson.
Impact of the COVID-19 pandemic on stage and incidence of head and neck cancer: A rapid review and meta-analysis.
Clin Otolaryngol., 49 (2024), pp. 363-375
[17]
J. Riju, A.J. Tirkey, M. Mathew, G. Chamania, M. Babu, S. Patil, et al.
Analysis of early impact of COVID-19 on presentation and management of oral cancers — an experience from a tertiary care hospital in South India.
Indian J Surg Oncol., 12 (2021), pp. 242-249
[18]
M. Szewczyk, J. Pazdrowski, P. Golusiński, P. Pazdrowski, B. Więckowska, W. Golusiński.
The impact of the COVID-19 pandemic on the management of head and neck cancer patients at a tertiary care institution in Poland.
Contemp Oncol (Pozn)., 25 (2021), pp. 264-269
[19]
K. Gršić, I. Blivajs, M. Pastorčić Grgić, D. Prgomet, J. Lukinović, O. Vugrinec, et al.
The impact of COVID-19 on head and neck cancer treatment delay.
Acta Clin Croat., 61 (2022), pp. 19-25
[20]
H.M. Peacock, C. de Gendt, G. Silversmit, S. Nuyts, J. Casselman, J.P. Machiels, et al.
Stage shift and relative survival for head and neck cancer during the 2020 COVID-19 pandemic: A population-based study of temporal trends.
Front Oncol., 13 (2023), pp. 1253968
[21]
J. Venkatasai, C. John, S.S. Kondavetti, M. Appasamy, L. Parasuraman, R. Ambalathandi, et al.
Impact of COVID-19 pandemic on patterns of care and outcome of head and neck cancer: Real-world experience from a tertiary care cancer center in India.
JCO Glob Oncol., 8 (2022), pp. e2100339
[22]
J.R. Bloom, C. Rodriguez-Russo, K. Hsieh, D.R. Dickstein, R.D. Sheu, M. Jain, et al.
Head and neck cancer patient population, management, and oncologic outcomes from the COVID-19 pandemic.
Curr Oncol., 31 (2024), pp. 436-446
[23]
J.E. Leeman, J.G. Li, X. Pei, P. Venigalla, Z.S. Zumsteg, E. Katsoulakis, et al.
Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques.
JAMA Oncol., 3 (2017), pp. 1487-1494
[24]
C.T. Haring, L.A. Kana, S.M. Dermody, C. Brummel, J.B. McHugh, K.A. Casper, et al.
Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.
Cancer., 129 (2023), pp. 2817-2827
asdasdasd
Opciones de artículo
Herramientas
Material suplementario